publication date: Jun. 5, 2020
NCI Trials for June 2020
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – NRG-GI007
Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma Who Are Not Candidates for Surgery
Ku, Geoffrey Yuyat
Phase I/II – 10313
A Phase IB and Randomized Open-Label Phase II Study of M6620 in Combination with Carboplatin/Gemcitabine/Avelumab in Patients with Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
University of Pittsburgh Cancer Institute LAO
Villaruz, Liza C.
Phase II – 10300
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia
Yale University Cancer Center LAO
Zeidan, Amer M.
Phase II – APEC1621M
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations
Children’s Oncology Group
Pratilas, Christine Anne
Phase II – EA5191
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
ECOG-ACRIN Cancer Research Group
Neal, Joel William
Phase II – TRC-10446
Tocilizumab in Hospitalized Cancer Patients with Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)
National Cancer Institute
Little, Richard Fowler
Phase III – A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Alliance for Clinical Trials in Oncology
Sands, Jacob M.
Phase III – NRG-CC005
FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
Schoen, Robert E.
Phase III – S1925
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Stephens, Deborah Marie
Phase III – WF-1901
Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
Wake Forest NCORP Research Base
Penzien, Donald B.
Phase Other – NCICOVID
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
National Cancer Institute
Korde, Larissa A.